Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Meeting MET-Amplified NSCLC With Progress

April 9th 2021

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss promising agents in the treatment of patients with non–small cell lung cancer with MET amplification.

What's Happening in KRAS G12C+ NSCLC?

April 9th 2021

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss the latest findings in KRAS G12C–positive non–small cell lung cancer.

Updates in EGFR+ NSCLC, Including Uncommon EGFR Mutations

April 9th 2021

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss data from the IASLC 2020 World Conference on Lung Cancer focused on EGFR-positive non–small cell lung cancer.

HER2-Directed Advances in Lung Cancer

April 9th 2021

Thoracic Night Live is devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.

Investigators Launch Epidemiology Study in Younger Patients With NSCLC

April 9th 2021

Investigators have launched the Epidemiology of Young Lung Cancer study to identify risk factors that can help shed light on why lung cancer develops in the younger population.

FDA Approval Insights: Trilaciclib in Extensive-Stage Small Cell Lung Cancer

April 8th 2021

Dr. Weiss discusses the significance of the FDA approval of trilaciclib in extensive-stage small cell lung cancer and key efficacy and safety data that have been reported with the CDK4/6 inhibitor.

Dr. Garon on Immunotherapy Treatment Considerations in NSCLC

April 8th 2021

Edward B. Garon, MD, discusses immunotherapy treatment considerations for patients with non–small cell lung cancer.

Lurbinectedin Approval Ignites a Spark for Precision Medicine in Small Cell Lung Cancer

April 7th 2021

Nisha A. Mohindra, MD, discusses the integration of lurbinectedin into the small cell lung cancer paradigm and remaining questions regarding future therapeutic directions.

Capmatinib for MET Exon 14-Mutated NSCLC

April 5th 2021

Discussion on the FDA approval of capmatinib, a MET inhibitor, as treatment for patients with MET exon 14-mutated non–small cell lung cancer based on data demonstrated by the GEOMETRY mono-1 study.

Testing to Identify MET Exon 14 Mutations in NSCLC

April 5th 2021

Recommendations for using next-generations sequencing panels as well as liquid biopsies to help identify MET exon 14 skipping mutations and other oncogenic drivers in patients with non–small cell lung cancer.

Lurbinectedin Makes a Splash in Second-Line SCLC

April 5th 2021

Wade T. Iams, MD, discusses the efficacy and safety of lurbinectedin in patients with small cell lung cancer, the impact of its approval on the paradigm, and remaining questions regarding its use.

Dr. Subramanian on the Efficacy of Selpercatinib in RET+ NSCLC

April 2nd 2021

Janakiraman Subramanian, MD, discusses the efficacy of selpercatinib in patients with RET fusion–positive non–small cell lung cancer.

Emerging Agents and Future of Small Cell Lung Cancer

April 2nd 2021

Jared Weiss, MD, and Stephen V. Liu, MD discuss treatment of small cell lung cancer and therapies in the pipeline.

Management of ES-SCLC: Second Line and Beyond

April 2nd 2021

Considerations for second-line treatment regimens, the role of immunotherapy in the relapsed/refractory setting, and using lurbinectedin for the management of ES-SCLC.

Using Trilaciclib for Treatment of ES-SCLC

April 2nd 2021

Stephen V. Liu, MD, and Jared Weiss, MD, share their thoughts on the impact of the recent approval of trilaciclib prior to platinum/etoposide-based chemotherapy for the treatment of ES-SCLC.

Patritumab Deruxtecan Under Exploration in Phase 2 HERTHENA-Lung01 Trial for EGFR+ NSCLC

April 1st 2021

The HER3-directed antibody-drug conjugate patritumab deruxtecan is under exploration in the treatment of patients with EGFR-mutated, metastatic or locally advanced non–small cell lung cancer who had previously received a TKI and platinum-based chemotherapy.

OncLive® Takes a Look Back at Most Listened Podcasts of 2020

April 1st 2021

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

Dr. Heymach on the Future of Immunotherapy in NSCLC

March 31st 2021

John V. Heymach, MD, PhD, discusses the future of immunotherapy in patients with non–small cell lung cancer.

Dr. Porter on Potential Sequencing With ADCs and TKIs in HER2+ Lung Cancer

March 31st 2021

Jason Porter, MD, discusses potential sequencing strategies with antibody-drug conjugates and TKIs in HER2-positive lung cancer.

Dr. Bazhenova on the Importance of Testing for HER2 Mutations in Lung Cancer

March 31st 2021

Lyudmila A. Bazhenova, MD, discusses the importance of testing for HER2 mutations in lung cancer.